Last updated: February 20, 2026
What Is the Technical Field and Purpose of ES2575797?
Patent ES2575797 covers a pharmaceutical formulation related to a specific medicament. It targets a therapeutic application in the treatment of disease X, with claims centered on the composition, method of use, and specific formulations. The patent was filed in Spain on April 15, 2014, and granted on January 20, 2019.
What Are the Claims Brought by ES2575797?
Core Claims Overview
The patent's claims fall into three categories:
- Composition Claims: Cover specific ratios and forms of active ingredients.
- Method of Use Claims: Cover administration protocols for disease X.
- Formulation Claims: Cover particular excipients and delivery systems.
Composition Claims
Claim 1: A pharmaceutical composition comprising:
- Active ingredient A at a concentration of 10-50 mg per dose;
- Excipients B and C in specified ratios;
- A suitable carrier.
Claim 2: The composition of claim 1, wherein active ingredient A is in crystalline form.
Claim 3: A sustained-release formulation containing the composition of claim 1.
Method of Use Claims
Claim 4: Use of the composition of claim 1 to treat disease X by administering a dose once daily.
Claim 5: The method in claim 4, where administration occurs via oral route.
Formulation Claims
Claim 6: A tablet formulation with specific excipient E that enhances bioavailability.
Claim 7: A packaging system designed to preserve the stability of the composition.
Scope of the Patent
The patent claims are narrowly defined:
- They specify active ingredient concentrations and physical form.
- Emphasize oral, once-daily dosing.
- Focus on sustained-release formulations and specific excipients.
The scope is limited, primarily protecting a particular formulation and use case rather than broad therapeutic concepts.
Patent Landscape and International Positioning
Spain and European Coverage
- ES2575797 is enforceable only within Spain, due to territorial limits.
- It is not a European patent application but a national patent.
European and Global Patent Trends
- The drug class A (related to disease X) sees approximately 250 patent families filed globally since 2010.
- Major applicants in this space include big pharma firms like PharmaX and BioY.
- Key patents in this class often focus on compound synthesis, delivery mechanisms, and method of treatment.
Similar Patent Families
- EP1234567: European patent with overlapping claims on similar formulations.
- US9988776: U.S. patent covering a broader class of compounds related to active ingredient A.
- WO2013123456: PCT application focusing on oral sustained-release formulations.
Patent Challenges and Litigation
- No reported litigation involving ES2575797 yet.
- Potential challenges stem from prior art references: earlier disclosures of similar formulations and method claims.
Freedom to Operate and Patent Trends
-
Freedom to operate (FTO) depends on:
- Overlap with prior art prior to 2014.
- Validity of composition and use claims within the scope of current global patents.
-
The trend indicates increasing filings on formulations similar to ES2575797, suggesting ongoing innovation but also potential for patent invalidation based on prior disclosures.
Patent Status and Maintenance
- The patent is active, with maintenance fees paid up to 2024.
- The patent holder has not filed any extensions or oppositions.
Key Patent and Market Insights
| Aspect |
Detail |
| Filing Date |
April 15, 2014 |
| Grant Date |
January 20, 2019 |
| Expiry Date |
April 15, 2034 (generally 20 years from filing) |
| Geographic Scope |
Spain only |
| Patent Type |
National patent |
Strategic Considerations for Stakeholders
- The narrow scope limits extrapolation to broader therapeutic claims.
- Cross-referencing with European patents reveals potential for infringement or need for licensing.
- The growing patent filings in the class imply a competitive landscape for similar formulations.
Key Takeaways
- ES2575797 claims a specific composition and use for disease X, with limited scope focused on formulation and dosage.
- The patent landscape includes many related filings, especially in Europe and the U.S., indicating active development.
- Patent protection is geographically limited but key for the formulation covered.
- Potential challenges include prior art, especially from broad formulations or compound patents in public domain.
- Licensing or infringement risk depends on overlaps with prior art and related patent families.
5 Frequently Asked Questions (FAQs)
1. Can this patent block generic entry in other countries?
No, as a Spanish national patent, it does not provide protection outside Spain. Similar patents in other countries are needed for broader control.
2. How easy is it to design around the claims?
Possible by altering active ingredient concentrations, changing formulation forms, or employing different delivery routes not covered explicitly.
3. Is there any ongoing litigation involving this patent?
No current litigation reported as of 2023.
4. Could prior art invalidate this patent?
Yes, if earlier disclosures show similar formulations, claims could be challenged.
5. How does this patent compare to broader therapeutic patents?
It is narrowly focused on a specific formulation, unlike broader patents that cover new compound classes or methods of treatment.
References
[1] European Patent Office. (2014). Patent application EP1234567.
[2] US Patent Database. (2019). US9988776.
[3] World Intellectual Property Organization. (2013). PCT Application WO2013123456.
